Akero Therapeutics (AKRO)
(Delayed Data from NSDQ)
$26.41 USD
+0.06 (0.23%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $26.41 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Brokerage Reports
Akero Therapeutics, Inc. [AKRO]
Reports for Purchase
Showing records 1 - 20 ( 108 total )
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
EFX Efficacy Continues to Improve Out to Week 96
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 SYNCHRONY Program Is Now Underway With Initiation of F4 MASH Outcomes Trial''s Initiation; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q Recap: SYNCHRONY Outcomes F4 MASH Study Initiation on Target in 2Q24; Cash Runway Extends Out to 2H27; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
96-Week HARMONY Data Demonstrates Unprecedented Fibrosis Improvement; Strong Validation for SYNCHRONY; Raise PT to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q Recap: 96-Week Results From Phase 2b HARMONY on Monday; EOP2 Meeting to Set the Tone for 2024; Raise PT to $43
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Enter a New Key Challenger in the MASH Race: Sagimet''s Denifanstat Looks to Enter Phase 3 by YE24
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 SYNCHRONY Program Underway; Next Quarter Is Key With Two Major Milestones For EFX; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for AKRO 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q Recap; EFX to Enter Pivotal Trials Imminently; SYNCHRONY on Target to Enroll First Patient By YE23; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Surprise Miss on 36-Week Fibrosis Improvement in Cirrhotic NASH Complicates the Regulatory Path Forward; PT to $40
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2b HARMONY Dataset Provides Exhaustive Review of EFX; Phase 2b SYMMETRY Top-Line Readout This Month; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q Recap; SYMMETRY Data in Cirrhotic Patients On Target in 4Q23; Initiations of SYNCHRONY Studies in 2H23; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
EFX + GLP-1 Combo Offers Substantial Benefit Over GLP-1s Alone, Exceeding Our Expectations; Raise PT to $64
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q Recap; SYMMETRY Cohort D Data On Target in 2Q23; Phase 3 SYNCHRONY Program Initiating in 2H23; Moderate PT to $62
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q Recap; NAVIGATE Phase 2b Interim Analysis On Target in 4Q24; Exploring Belapectin Oncology Opportunities; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q Recap; SYMMETRY Cohort D Data in 2Q23; FDA Meeting This Month to Determine EFX Phase 3 Study Design; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2b SYMMETRY and Cohort D Complete Enrollment; Expecting Three Major Milestones in 2023; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
EFX Granted Breakthrough Therapy Designation in Less Than Three Months After Topline HARMONY Data; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E